AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from 11 analysts (9 buy, 1 hold, 1 sell) with an average 12‑month price target of $75.50.
• AnaptysBio beat expectations with $1.58 EPS vs. $0.89 expected and revenue of $108.25M vs. $87.09M, and the stock rose about 14.8% following the results.
• The company announced a share repurchase plan, while insiders have recently sold stock (CEO sold 17,679 shares; insiders sold 48,324 shares totaling ~$2.79M) but still own 33.5% of shares.

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $75.50.

Several research firms recently issued reports on ANAB. Wedbush upped their price objective on AnaptysBio from $60.00 to $75.00 and gave the company an "outperform" rating in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Piper Sandler upped their price objective on AnaptysBio from $67.00 to $95.00 and gave the company an "overweight" rating in a research report on Tuesday, March 31st. Barclays lowered their price objective on AnaptysBio from $79.00 to $63.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, UBS Group lowered their price objective on AnaptysBio from $90.00 to $60.00 and set a "buy" rating on the stock in a research report on Tuesday.

AnaptysBio Stock Up 14.8%

Shares of ANAB opened at $58.88 on Friday. The business's 50 day moving average price is $60.00 and its 200-day moving average price is $48.75. AnaptysBio has a 52 week low of $17.11 and a 52 week high of $73.30. The stock has a market cap of $1.69 billion, a P/E ratio of -113.23 and a beta of 0.40.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The firm had revenue of $108.25 million for the quarter, compared to analysts' expectations of $87.09 million. On average, equities analysts anticipate that AnaptysBio will post -2.96 EPS for the current year.

AnaptysBio declared that its board has initiated a stock repurchase plan on Friday, March 27th that allows the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its stock is undervalued.

Insider Activity at AnaptysBio

In related news, CEO Daniel Faga sold 17,679 shares of the company's stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the transaction, the chief executive officer directly owned 495,965 shares of the company's stock, valued at approximately $30,556,403.65. This represents a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John P. Schmid sold 20,645 shares of the company's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director directly owned 31,622 shares in the company, valued at $1,774,310.42. This trade represents a 39.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 48,324 shares of company stock valued at $2,787,594. 33.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC raised its stake in AnaptysBio by 1.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company's stock valued at $732,000 after buying an additional 225 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company's stock valued at $65,000 after buying an additional 263 shares during the last quarter. Larson Financial Group LLC raised its stake in AnaptysBio by 21.2% during the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company's stock valued at $79,000 after buying an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its stake in AnaptysBio by 1.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company's stock valued at $1,743,000 after buying an additional 500 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock valued at $40,000 after buying an additional 821 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.